GLP‑1 coverage narrows in US
- Forbes reported on April 25 that Medicaid coverage for GLP-1 obesity drugs has narrowed in 2026, even as Medicare prepares a new bridge program and CMS invites states into its BALANCE model. - As of January 2026, only 13 state Medicaid fee-for-service programs covered GLP-1s for obesity, down from 16 states in 2025, according to the Forbes report. - KFF says obesity-drug coverage is optional in Medicaid, and tighter state budgets are pushing some programs to reassess access. (kff.org)
Access to GLP-1 weight-loss drugs is tightening in Medicaid even as Medicare prepares to open a new pathway later this year. (forbes.com) (cms.gov) Forbes reported April 25 that only 13 state Medicaid fee-for-service programs covered GLP-1 therapy for obesity as of January 2026, down from 16 states in 2025. The pullback comes as demand for Wegovy and Zepbound remains high. (forbes.com) GLP-1 drugs mimic a gut hormone that slows digestion and reduces appetite. They were first used for type 2 diabetes, then expanded into obesity care after trials showed large weight-loss effects. (kff.org) Medicaid must cover these drugs for diabetes and some other approved uses, but obesity treatment is different. Federal law lets states decide whether to cover weight-loss drugs in Medicaid, so access changes by ZIP code. (kff.org) KFF said in January that state Medicaid programs are re-evaluating obesity-drug coverage as budgets tighten after the 2025 reconciliation law cut federal Medicaid funding. The group also said upfront GLP-1 costs remain a central concern for public payers. (kff.org) At the same time, the federal government is moving the other way for some older Americans. CMS said on March 9 that state Medicaid agencies and Medicare Part D sponsors can apply for the BALANCE model, with participating states launching as early as May 2026. (cms.gov) CMS also said a separate “Medicare GLP-1 Bridge” demonstration will begin in July 2026. The agency said that program is meant to give eligible Medicare Part D beneficiaries access to GLP-1 medications before the broader model reaches Part D in January 2027. (cms.gov) That leaves 2026 looking split-screen: narrower Medicaid obesity coverage in some states, and a new federal push to lower costs for selected Medicare and Medicaid participants. Patients who lose state coverage may be left with prior authorization fights, cash-pay programs, or no access at all. (forbes.com) (kff.org) The next test is whether states join BALANCE and whether lower net prices change Medicaid decisions. For now, the map is shrinking, not expanding. (cms.gov) (forbes.com)
